Ilumya Generic Name & Formulations
Tildrakizumab-asmn 100mg/mL; soln for SC inj; preservative-free.
Single-dose prefilled syringe—1 (w. needle guard + cover)
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Ilumya Dosage and Administration
Give by SC inj in abdomen, thighs, or upper arm. ≥18yrs: 100mg at Weeks 0 and 4, then every 12 weeks thereafter.
<18yrs: not established.
Ilumya Boxed Warnings
Should only be administered by a healthcare provider. Discontinue if serious hypersensitivity reaction occurs; treat appropriately. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for tuberculosis (TB) infection prior to initiating. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.
Concomitant live vaccines: not recommended.
Ilumya Adverse Reactions
Upper respiratory infections, inj site reactions, diarrhea; hypersensitivity reactions.
Ilumya Clinical Trials
Ilumya Patient Counseling